{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:11:06Z","timestamp":1793157066510,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ahj.2023.05.002","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T11:05:09Z","timestamp":1683543909000},"page":"104-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry"],"prefix":"10.1016","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3367-0302","authenticated-orcid":false,"given":"Suzanne V.","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensey","family":"Gosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence S.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory L.","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Hamersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigar","family":"Rajpura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ahj.2023.05.002_bib0001","first-page":"S1","article-title":"Standards of medical care in diabetes","volume":"40","author":"Association","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2023.05.002_bib0002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2337\/diaclin.29.3.116","article-title":"Microvascular and macrovascular complications of diabetes","volume":"3","author":"Fowler","year":"2011","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.ahj.2023.05.002_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109218","article-title":"Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study","volume":"185","author":"Nicolucci","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.ahj.2023.05.002_bib0004","doi-asserted-by":"crossref","first-page":"e00321","DOI":"10.1002\/edm2.321","article-title":"Impact of micro- and macrovascular complications of type 2 diabetes on quality of life: insights from the DISCOVER prospective cohort study","volume":"5","author":"Arnold","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.ahj.2023.05.002_bib0005","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/diacare.26.3.917","article-title":"American diabetes A. Economic costs of diabetes in the US in 2002","volume":"26","author":"Hogan","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2023.05.002_bib0006","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.106.179294","article-title":"Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"115","author":"Buse","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2023.05.002_bib0007","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/01.CIR.100.10.1134","article-title":"Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association","volume":"100","author":"Grundy","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2023.05.002_bib0008","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jdiacomp.2005.06.013","article-title":"The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA cooperative study in diabetes","volume":"20","author":"Kirkman","year":"2006","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.ahj.2023.05.002_bib0009","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/jama.2019.3471","article-title":"Resurgence in diabetes-related complications","volume":"321","author":"Gregg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2023.05.002_bib0010","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ahj.2023.05.002_bib0011","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2023.05.002_bib0012","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1177\/2047487317729252","article-title":"Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR(R) research to practice project","volume":"24","author":"Arnold","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ahj.2023.05.002_bib0013","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","article-title":"CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries","volume":"20","author":"Mosenzon","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ahj.2023.05.002_bib0014","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.2337\/dc16-0585","article-title":"Evaluating the quality of comprehensive cardiometabolic care for patients with type 2 diabetes in the U.S.: The diabetes collaborative registry","volume":"39","author":"Arnold","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2023.05.002_bib0015","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2023.05.002_bib0016","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2023.05.002_bib0017","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2023.05.002_bib0018","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","article-title":"Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association","volume":"141","author":"Arnold","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ahj.2023.05.002_bib0019","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2023.05.002_bib0020","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2337\/db21-324-OR","article-title":"Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes: results from DISCOVER","volume":"70","author":"Arnold","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.ahj.2023.05.002_bib0021","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/CIRCULATIONAHA.119.041730","article-title":"Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease","volume":"140","author":"Arnold","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2023.05.002_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/17539447221113946","article-title":"Polypharmacy among older individuals with heart failure: trends between 2000 and 2017 in the province of Quebec, Canada","volume":"16","author":"Campeau Calfat","year":"2022","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.ahj.2023.05.002_bib0023","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/ehjcvp\/pvz058","article-title":"Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice","volume":"6","author":"Slater","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ahj.2023.05.002_bib0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.03.017","article-title":"Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits","volume":"224","author":"Gao","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2023.05.002_bib0025","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2023.05.002_bib0026","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2023.05.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007682","article-title":"Cardiometabolic center of excellence: a novel care delivery model for secondary prevention of cardiovascular disease in type 2 diabetes","volume":"14","author":"Thomas","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2023.05.002_bib0028","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11886-022-01715-3","article-title":"Synchronous health care delivery for the optimization of cardiovascular and renal care in patients with type 2 diabetes","volume":"24","author":"Alqahtani","year":"2022","journal-title":"Curr Cardiol Rep"},{"issue":"8","key":"10.1016\/j.ahj.2023.05.002_bib0029","first-page":"979","article-title":"Inadequate use of newer treatments and glycemic control by cardiovascular risk and sociodemographic groups in US adults with diabetes in the NIH precision medicine initiative all of us research program","volume":"24","author":"Devineni","year":"2022","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870323001126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870323001126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:10:48Z","timestamp":1757571048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870323001126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":29,"alternative-id":["S0002870323001126"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2023.05.002","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2023.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}